Phase 2 Advancement

RBB's lead candidate, RB‑190, has demonstrated reversal of key disease pathologies in preclinical models and multiple published studies, supporting advancement into Phase 2 clinical development. The company's founder and CEO, Jonathan Sackner‑Bernstein, expressed enthusiasm for the partnership, highlighting its potential to accelerate the development of a novel Parkinson's therapy.